--- title: "Acurx Pharmaceuticals (ACXP) news: offering and Nasdaq notice" url: "https://aibio.space/companies/acurx-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ACXP offering and Nasdaq notice news: Acurx Pharmaceuticals prices $2.5 million registered direct offering with warrants. Acurx Pharmaceuticals, Inc." --- ACXP Acurx Pharmaceuticals, Inc. NASDAQ · United States # Acurx Pharmaceuticals (ACXP) news ACXP offering and Nasdaq notice news Financings · 2026-04-16 ## [Acurx Pharmaceuticals prices $2.5 million registered direct offering with warrants](https://aibio.space/news/acurx-pharmaceuticals-prices-2-5-million-registered-direct-offering/) Acurx agreed to sell 816,068 shares at $3.03 and pre-funded warrants for 9,017 shares, plus Series H warrants at $2.78 in a concurrent private placement. H.C. Wainwright & Co., LLC is the placement agent, and the 10-K says existing resources will not fund operations for at least 12 months. ## Latest Acurx Pharmaceuticals news 1. 2025-03-28 Listings [Acurx Pharmaceuticals gets Nasdaq stockholders' equity deficiency notice](https://aibio.space/news/acurx-pharmaceuticals-gets-nasdaq-stockholders-equity-deficiency/) Acurx Pharmaceuticals received a Nasdaq letter saying it no longer meets the $2,500,000 stockholders' equity minimum for the Capital Market. The company must submit a plan to regain compliance by May 9, 2025, and the notice rests on its 2024 annual report. 2. 2025-03-10 Financings [Acurx Pharmaceuticals agrees to $1.1 million registered direct offering at $0.40 a share](https://aibio.space/news/acurx-pharmaceuticals-agrees-1-1-million-registered-direct-offering-0/) Acurx Pharmaceuticals sold 2,150,000 shares and pre-funded warrants for 595,000 more at about $0.40 each, and added private warrants for up to 8,235,000 shares. The price is far below the $1.015 the company got in a January offering, and a Nasdaq bid-price notice arrived on February 24, 2025. 3. 2025-01-07 Financings [Acurx Pharmaceuticals prices $2.5 million registered direct offering at $1.015 per share](https://aibio.space/news/acurx-pharmaceuticals-prices-2-5-million-registered-direct-offering-1/) Acurx will sell 2,463,058 shares at $1.015 to institutional investors and six insiders, with Series E warrants for the same number of shares at $0.90. H.C. Wainwright & Co. is the exclusive placement agent, and it receives a 7.0% cash fee plus a 1.0% management fee. ## Acurx Pharmaceuticals at a glance - **Ticker**: ACXP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $10.7 million ### Related companies - [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) NASDAQ: REGN - [Biogen](https://aibio.space/companies/biogen/) NASDAQ: BIIB - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) NASDAQ: LTGO - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) AMEX: MTNB - [Vyome Holdings](https://aibio.space/companies/vyome/) NASDAQ: HIND - [Savara](https://aibio.space/companies/savara/) NASDAQ: SVRA - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) NASDAQ: ACRS - [Damora Therapeutics](https://aibio.space/companies/damora-therapeutics/) NASDAQ: DMRA ### Also on NASDAQ - [Cogent Biosciences](https://aibio.space/companies/cogent-biosciences/) COGT - [TACTILE SYSTEMS TECHNOLOGY INC](https://aibio.space/companies/tactile-systems-technology/) TCMD - [AETHLON MEDICAL INC](https://aibio.space/companies/aethlon-medical/) AEMD - [Anbio Biotechnology](https://aibio.space/companies/anbio-biotechnology/) NNNN - [Evolus](https://aibio.space/companies/evolus/) EOLS - [Ligand Pharmaceuticals](https://aibio.space/companies/ligand-pharmaceuticals/) LGND ## What Acurx Pharmaceuticals does Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its candidates have a Gram-positive selective spectrum and block DNA polymerase IIIC (pol IIIC), an enzyme that is the primary catalyst for DNA replication in several Gram-positive bacteria. Its lead antibiotic candidate, ibezapolstat, targets Clostridioides difficile infection. The company says Phase 2 clinical data validated the efficacy of ibezapolstat and of pol IIIC as an antibacterial target, and that it is ready to enter Phase 3 trials. It expects to partner with a fully integrated pharmaceutical company for late-stage trials and commercialization. Its early-stage pipeline includes ACX-375C, a potential oral and parenteral treatment for Gram-positive bacteria including MRSA and VRE, which has proof of concept in animal studies. The pipeline also targets drug-resistant Streptococcus pneumoniae and B. anthracis. The company describes these pathogens as priority pathogens listed by the WHO, the CDC and the FDA. It states it has no commitments from potential partners or others to provide capital, and it continues to evaluate potential strategic transactions. | Product or program | What it is | Stage | |---|---|---| | Ibezapolstat | Oral pol IIIC inhibitor antibiotic for Clostridioides difficile infection | Phase 2 completed; ready to enter Phase 3 | | ACX-375C | Potential oral and parenteral antibiotic for Gram-positive bacteria including MRSA and VRE | early-stage; proof of concept in animal studies | Summarised from the company's [10-K filed Mar 12, 2026](https://www.sec.gov/Archives/edgar/data/1736243/000110465926027052/acxp-20251231x10k.htm). ## Acurx Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$1.8 million](https://www.sec.gov/Archives/edgar/data/1736243/000110465926027052/) | [$5.4 million](https://www.sec.gov/Archives/edgar/data/1736243/000110465926027052/) | | Net income (loss) | [-$8.0 million](https://www.sec.gov/Archives/edgar/data/1736243/000110465926027052/) | [-$14.1 million](https://www.sec.gov/Archives/edgar/data/1736243/000110465926027052/) | | Cash from operations | [-$6.8 million](https://www.sec.gov/Archives/edgar/data/1736243/000110465926027052/) | [-$10.4 million](https://www.sec.gov/Archives/edgar/data/1736243/000110465926027052/) | | Cash and equivalents | [$7.6 million](https://www.sec.gov/Archives/edgar/data/1736243/000110465926095904/) | [$3.7 million](https://www.sec.gov/Archives/edgar/data/1736243/000110465926095904/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $10.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Acurx Pharmaceuticals Has Acurx Pharmaceuticals raised money recently? Our latest story on this, dated Apr 16, 2026: "Acurx Pharmaceuticals prices $2.5 million registered direct offering with warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/acurx-pharmaceuticals-prices-2-5-million-registered-direct-offering/). Has Acurx Pharmaceuticals received a Nasdaq deficiency notice? Our latest story on this, dated Mar 28, 2025: "Acurx Pharmaceuticals gets Nasdaq stockholders' equity deficiency notice". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/acurx-pharmaceuticals-gets-nasdaq-stockholders-equity-deficiency/). What is the ticker symbol of Acurx Pharmaceuticals? Acurx Pharmaceuticals, Inc. trades under the ticker ACXP on NASDAQ. Where is Acurx Pharmaceuticals listed? Acurx Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Acurx Pharmaceuticals? The SEC Central Index Key (CIK) for Acurx Pharmaceuticals, Inc. is 1736243. Its filings are on SEC EDGAR. How many shares does Acurx Pharmaceuticals have outstanding? 5,269,921 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Acurx Pharmaceuticals listed under? Our directory records Acurx Pharmaceuticals, Inc. under United States. What does Acurx Pharmaceuticals do? Our directory classifies Acurx Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Acurx Pharmaceuticals? The ISIN recorded for Acurx Pharmaceuticals, Inc. is US00510M2035. Does aibio.space cover Acurx Pharmaceuticals? aibio.space lists Acurx Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Acurx Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Acurx Pharmaceuticals develop? Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its candidates have a Gram-positive selective spectrum and block DNA polymerase IIIC (pol IIIC), an enzyme that is the primary catalyst for DNA replication in several Gram-positive bacteria. What is Ibezapolstat from Acurx Pharmaceuticals? Ibezapolstat: Oral pol IIIC inhibitor antibiotic for Clostridioides difficile infection Stage: Phase 2 completed; ready to enter Phase 3. What is ACX-375C from Acurx Pharmaceuticals? ACX-375C: Potential oral and parenteral antibiotic for Gram-positive bacteria including MRSA and VRE Stage: early-stage; proof of concept in animal studies. Is Acurx Pharmaceuticals profitable? Acurx Pharmaceuticals, Inc. reported a net loss of $8.0 million for the fiscal year ended Dec 31, 2025, and used $6.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Acurx Pharmaceuticals Members talk about Acurx Pharmaceuticals (ACXP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Acurx Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-04-16 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465926044092/tm2611961d1_424b5.htm) 2. 2025-07-31 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465925072529/tm2521773d1_ex99-1.htm) 3. 2025-07-17 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465925068659/tm2521097d1_8k.htm) 4. 2025-07-09 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465925066693/tm2519344d1_s3.htm) 5. 2025-05-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465925054235/tm252476-3_def14a.htm) 6. 2025-05-19 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465925050438/tm252476-1_pre14a.htm) 7. 2025-05-08 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465925046167/tm2514277d1_8k.htm) 8. 2025-03-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465925029370/tm2510590d1_8k.htm) 9. 2025-03-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465925021975/tm258693d1_424b5.htm) 10. 2025-02-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1736243/000110465925017437/tm257571d1_8k.htm) 11. 2025-01-31 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1736243/000141057825000067/acxp-20240930xs1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ACXP on TradingView](https://www.tradingview.com/symbols/NASDAQ-ACXP/). ## SEC filings and registration - **SEC name**: Acurx Pharmaceuticals, Inc. - **CIK**: 1736243 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ACXP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 259 LIBERTY AVENUE, STATEN ISLAND, NY, 10305 - **Phone**: 917-533-1469 - **Shares outstanding**: 5,269,921 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: Acurx Pharmaceuticals, LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1736243/000110465926116632/tm2627481d1_8k.htm) filed 2026-10-16 - [S-1](https://www.sec.gov/Archives/edgar/data/1736243/000110465926105917/tm2624622-1_s1.htm) filed 2026-09-08 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1736243/000110465926104316/tm262428-1_def14a.htm) filed 2026-09-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1736243/000110465926095904/acxp-20260630x10q.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1736243/000110465926058631/acxp-20260331x10q.htm) filed 2026-05-11 - [S-1](https://www.sec.gov/Archives/edgar/data/1736243/000110465926054887/tm2611792d1_s1.htm) filed 2026-05-04 - [S-1](https://www.sec.gov/Archives/edgar/data/1736243/000110465926054884/tm2611792d2_s1.htm) filed 2026-05-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1736243/000110465926044093/tm2611957d1_8k.htm) filed 2026-04-16 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001736243), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Acurx Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ACXP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Acurx Pharmaceuticals, Inc. - **Ticker**: ACXP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US00510M2035 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ACXP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/acurx-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Acurx Pharmaceuticals (ACXP) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/acurx-pharmaceuticals/